Literature DB >> 23240798

Prolapse and sexual function in women with benign joint hypermobility syndrome.

H Mastoroudes1, I Giarenis1, L Cardozo1, S Srikrishna1, M Vella1, D Robinson2, H Kazkaz2, R Grahame2.   

Abstract

OBJECTIVE: To determine whether pelvic organ prolapse (POP) and sexual dysfunction are more severe in women with benign joint hypermobility syndrome (BJHS) than in the normal population.
DESIGN: Case-control study.
SETTING: King's College Hospital NHS Foundation Trust, London, UK and University College Hospital, London, UK. POPULATION: Women diagnosed with BJHS (n = 60) at University College Hospital. Control participants (n = 60) recruited from King's College Hospital NHS Foundation Trust.
METHODS: Objective assessment of POP was undertaken using the Pelvic Organ Prolapse Quantification System (POP-Q). Both groups were asked to complete the Prolapse quality of life (P-QOL) and pelvic organ prolapse/urinary incontinence sexual (PISQ-12) questionnaires. MAIN OUTCOME MEASURES: Comparison of vaginal anatomy using POP-Q between the two groups. Comparison of P-QOL and PISQ-12 quality of life scores between the two groups.
RESULTS: In all, 120 women (60 in Study group, 60 in Control group) were recruited. All women in the study group were matched with healthy control women according to age, parity and ethnicity. There was a statistically significant difference between points Aa, Ba, Ap, Bp and C in study and control groups showing that prolapse is objectively more severe in those with BJHS. Significantly more women with BJHS felt that POP interfered with sex and defecation compared with the control group. The impact of prolapse symptoms on quality of life was statistically different in almost all nine P-QOL domains.
CONCLUSIONS: A large number of women with BJHS have prolapse symptoms, which significantly affect their quality of life. POP is more severe in women with BJHS.
© 2013 The Authors BJOG An International Journal of Obstetrics and Gynaecology © 2013 RCOG.

Entities:  

Mesh:

Year:  2013        PMID: 23240798     DOI: 10.1111/1471-0528.12082

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  8 in total

Review 1.  Urogenital and pelvic complications in the Ehlers-Danlos syndromes and associated hypermobility spectrum disorders: A scoping review.

Authors:  Elizabeth Gilliam; Jodi D Hoffman; Gloria Yeh
Journal:  Clin Genet       Date:  2019-09-01       Impact factor: 4.438

Review 2.  The clinical physiotherapy assessment of non-traumatic shoulder instability.

Authors:  Catherine Barrett
Journal:  Shoulder Elbow       Date:  2014-09-04

3.  Generalized joint hypermobility and voiding dysfunction in children: is there any relationship?

Authors:  Abdol-Mohammad Kajbafzadeh; Lida Sharifi-Rad; Seyedeh Sanam Ladi Seyedian; Sarah Mozafarpour; Koosha Paydary
Journal:  Eur J Pediatr       Date:  2014-02       Impact factor: 3.183

Review 4.  Clinical Relevance of Joint Hypermobility and Its Impact on Musculoskeletal Pain and Bone Mass.

Authors:  Vito Guarnieri; Marco Castori
Journal:  Curr Osteoporos Rep       Date:  2018-08       Impact factor: 5.096

Review 5.  Prevention and management of pelvic organ prolapse.

Authors:  Ilias Giarenis; Dudley Robinson
Journal:  F1000Prime Rep       Date:  2014-09-04

Review 6.  Hypermobile Ehlers-Danlos syndrome and disorders of the gastrointestinal tract: What the gastroenterologist needs to know.

Authors:  Phoebe A Thwaites; Peter R Gibson; Rebecca E Burgell
Journal:  J Gastroenterol Hepatol       Date:  2022-07-20       Impact factor: 4.369

Review 7.  Association between joint hypermobility and pelvic organ prolapse in women: a systematic review and meta-analysis.

Authors:  Nikolaus Veit-Rubin; Rufus Cartwright; Anand U Singh; G Alessandro Digesu; Ruwan Fernando; Vikram Khullar
Journal:  Int Urogynecol J       Date:  2015-12-10       Impact factor: 2.894

Review 8.  Hypermobile Ehlers-Danlos syndromes: Complex phenotypes, challenging diagnoses, and poorly understood causes.

Authors:  Cortney Gensemer; Randall Burks; Steven Kautz; Daniel P Judge; Mark Lavallee; Russell A Norris
Journal:  Dev Dyn       Date:  2020-08-17       Impact factor: 3.780

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.